Linaclotide Therapy for Gastrointestinal Disorders

Indications and Usage

The American Gastroenterological Association strongly recommends linaclotide as a second-line agent for irritable bowel syndrome with constipation (IBS-C) after inadequate response to first-line therapies, particularly for patients with concurrent bloating, abdominal discomfort, and pain symptoms 1
Linaclotide is effective for patients with IBS-C, achieving a FDA composite endpoint (≥30% reduction in abdominal pain AND ≥1 complete spontaneous bowel movement increase per week) in 34% of patients vs 19% with placebo 1
The AGA-ACG guideline recommends linaclotide for adults with chronic idiopathic constipation (CIC) who do not respond adequately to over-the-counter laxatives, with a significant increase in complete spontaneous bowel movements by 1.37 per week compared to placebo 2

Linaclotide improves global IBS symptom relief in 71% of patients vs placebo, and is particularly useful when abdominal symptoms (bloating, discomfort) coexist with constipation 1
Diarrhea is the most common and clinically significant adverse effect, occurring in 16.3% of IBS-C patients (290 mcg dose) compared to 2.3% with placebo, and leads to treatment discontinuation in 3.4-4.7% of patients 1, 2, 3
Linaclotide has a high certainty of evidence supporting its use for both IBS-C and CIC, and ranks first in efficacy among secretagogues for IBS-C according to network meta-analysis 1, 2

Linaclotide is contraindicated in patients less than 2 years of age due to risk of fatal dehydration, and in known or suspected mechanical GI obstruction 2
Patients on diuretics or other medications affecting sodium balance may have higher hyponatremia risk, and should be monitored for electrolyte imbalances 5

Patients should be monitored for bowel movement frequency and consistency, diarrhea severity and frequency, and abdominal pain improvement (in IBS-C patients) 1, 2, 3
If diarrhea occurs and is problematic, consider dose reduction or switching to lubiprostone (8 mcg twice daily), which has significantly lower diarrhea rates (4.3% vs 16.3%) 2, 4